Capreomycin sulfate: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
|||
| Line 22: | Line 22: | ||
'''| [[Capreomycin sulfate adverse reactions|Adverse Reactions]]''' | '''| [[Capreomycin sulfate adverse reactions|Adverse Reactions]]''' | ||
'''| [[Capreomycin sulfate overdosage|Overdosage]]''' | '''| [[Capreomycin sulfate overdosage|Overdosage]]''' | ||
'''| [[Capreomycin sulfate dosage and administration|Dosage and Administration]]''' | '''| [[Capreomycin sulfate dosage and administration|Dosage and Administration]]''' | ||
'''| [[Capreomycin sulfate how supplied|How Supplied]]''' | '''| [[Capreomycin sulfate how supplied|How Supplied]]''' | ||
'''| [[Capreomycin sulfate labels and packages|Labels and Packages]]''' | '''| [[Capreomycin sulfate labels and packages|Labels and Packages]]''' | ||
Revision as of 23:58, 25 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Capreomycin is a peptide antibiotic, commonly grouped with the aminoglycosides, which is given in combination with other antibiotics for MDR-tuberculosis. Adverse effects include nephrotoxicity and 8th cranial auditory vestibular nerve nerve toxicity.
Category
Antimycobacterial
US Brand Names
CAPASTAT SULFATE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages